CAR-T Cell Therapies Entering The Mainstream Of Cancer Clinical Trials & Treatment

Managing Editor of Pharmaceutical Technology Jeanne Linke Northrop recently held an interview with Tanmay Jain, Sr. Director of Trial Design Solutions within Medidata AI, about the use of CAR-T cell therapies within the oncology space.

Despite their remarkable potential to transform the field of oncology, CAR-T cell therapies have posed significant challenges for clinical trials and developers since the first CAR-T patient was treated a decade ago. The occurrence of adverse events, including Cytokine Release Syndrome (CRS), has imposed limitations on the eligible patient population, treatment locations, and financial feasibility.

Nevertheless, Medidata AI's predictive trial design enables developers to glean insights from both successful and unsuccessful CAR-T clinical trials. This empowers them to conduct future trials more efficiently and safely by identifying high-risk patients prone to adverse events like CRS and implementing preemptive treatments for better patient management.

Learn more about this technology and the use of CAR-T cell therapies in clinical trials and cancer research by watching the full webinar.